<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345382</url>
  </required_header>
  <id_info>
    <org_study_id>16520</org_study_id>
    <secondary_id>2014-000410-57</secondary_id>
    <nct_id>NCT02345382</nct_id>
  </id_info>
  <brief_title>Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia</brief_title>
  <official_title>An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety, tolerability, pharmacokinetics, maximum tolerated dose, and
      recommended Phase II dose of BAY1143572 in a once-daily or an intermittent dosing schedule in
      subjects with advanced acute leukemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2015</start_date>
  <completion_date type="Actual">July 30, 2017</completion_date>
  <primary_completion_date type="Actual">September 14, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BAY1143572 in advanced acute leukemia patients</measure>
    <time_frame>After 28 days treatment</time_frame>
    <description>The MTD is defined as the highest dose that can be given such that not more than 20% of subjects experience a dose limiting toxicity (DLT) during Cycle 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukemia response evaluation</measure>
    <time_frame>Up to 2 years at the end of each cycle</time_frame>
    <description>The efficacy evaluation will be based on the revised recommendations of the International Working Group (IWG) for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic studies in acute myeloid leukemia (Cheson et al. 2003). The same criteria will be used for acute lymphoblastic leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 2 years until LPLV</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum total drug concentration in plasma after a single dose) of BAY1143572</measure>
    <time_frame>Multiple timepoints on Cycle 1 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,md (maximum total drug concentration in plasma after multiple dose) of BAY1143572</measure>
    <time_frame>Multiple timepoints on Cycle 1 Day 15 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-24) (area under the concentration versus time curve from zero to infinity after single (first) dose) of BAY1143572</measure>
    <time_frame>Multiple timepoints on Cycle 1 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-24)md (area under the concentration versus time curve from zero to infinity after multiple dose) of BAY1143572</measure>
    <time_frame>Multiple timepoints on Cycle 1 Day 15 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-tlast) (area under the concentration versus time curve from time 0 to the last data point&gt;LLOQ after single dose) of BAY1143572</measure>
    <time_frame>Multiple timepoints on Cycle 1 Day 1</time_frame>
    <description>LLOQ: lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time to reach Cmax after single dose) of BAY1143572</measure>
    <time_frame>Multiple timepoints on Cycle 1 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,md (time to reach Cmax after multiple dose) of BAY1143572</measure>
    <time_frame>Multiple timepoints on Cycle 1 Day 15 and 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>BAY1143572 (continuous dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1143572 will be administered from Cycle1 Day1 onwards once daily continuously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1143572 (intermittent dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1143572 will be administered from Cycle1 Day1 onwards in an intermittent dosing schedule. Based on nonclinical pharmacology results, a 3 days on / 4 days off schedule is used as intermittent dosing schedule in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1143572</intervention_name>
    <description>The starting dose will be 20 mg BAY 1143572. Maximum dose escalation between dose levels will be 2 fold.The dose-escalation part of each dosing schedule may be followed by an expansion part.</description>
    <arm_group_label>BAY1143572 (continuous dosing)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1143572</intervention_name>
    <description>As soon as the MTD has been determined for the once-daily continuous dosing schedule (i.e. Study Arm 1), Study Arm 2 will be opened, testing a 3 days on / 4 days off dosing schedule. The starting dose for Study Arm 2 will be the MTD of BAY1143572 determined in Study Arm 1.
Maximum dose escalation between dose levels will be 2 fold. The dose-escalation part of each dosing schedule may be followed by an expansion part.</description>
    <arm_group_label>BAY1143572 (intermittent dosing)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged &gt;/=18 years

          -  Subjects with a histologically or cytologically confirmed acute leukemia who are
             refractory to or have exhausted all available therapies

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Life expectancy of at least 12 weeks

          -  Adequate liver and renal functions as assessed by the following laboratory
             requirements to be conducted within 14 days before the first dose of study drug:

               -  Total bilirubin &lt;/=1.5 times the upper limit of normal (ULN)

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt;/=2.5 times
                  ULN (&lt;/=5 times ULN for subjects with liver involvement of their cancer)

               -  International normalized ratio (INR) &lt;/=1.5 times ULN

               -  Estimated glomerular filtration rate (eGFR) &gt;/=50 mL/min per 1.73 m2 according to
                  the Modification of Diet in Renal Disease Study Group (MDRD) formula

          -  Negative serum or urine pregnancy test must be obtained within 7 days before the first
             dose of study drug in women of childbearing potential. Negative results must be
             available before study drug administration

          -  Women and men of reproductive potential must agree to use highly effective
             contraception when sexually active. This applies for the period between signing of the
             informed consent and 30 days after the last administration of study drug. Highly
             effective contraception includes a hormonal contraception with implants or combined
             oral contraceptives, certain intrauterine devices, bilateral tubal ligation,
             hysterectomy, or vasectomy of the partner. In addition, the use of condoms for
             subjects or their partners is required.

        Exclusion Criteria:

          -  Known hypersensitivity to the study drug or excipients of the preparation or any agent
             given in association with this study

          -  History of cardiac disease including congestive heart failure New York Heart
             Association (NYHA) Class &gt;/=III, unstable angina (anginal symptoms at rest) or
             new-onset angina (within the last 6 months) or myocardial infarction within the past 6
             months or cardiac arrhythmias requiring anti-arrhythmic therapy except for
             beta-blockers and digoxin; evidence for uncontrolled coronary artery disease (e.g.
             major regional wall motion abnormalities on baseline echocardiography or a left
             ventricular ejection fraction (LVEF) &lt;45%)

          -  Previous pulmonary embolism within 12 months before study entry

          -  Uncontrolled hypertension defined as systolic blood pressure &gt;160 mmHg or diastolic
             blood pressure &gt;100 mmHg, despite optimal medical management and stable
             antihypertensive treatment for more than 7 days before the first dose of study drug

          -  Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Chronic or active hepatitis B or C, requiring antiviral therapy

          -  Serious, uncontrolled infection requiring systemic antibiotic, antifungal or antiviral
             therapy

          -  Uncontrolled meningeal leukemia

          -  Prior allogeneic hematopoietic stem cell transplant within &lt;/=4 months before first
             dose of study drug (Subjects must have completed immunosuppressive therapy before
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Johann Wolfgang Goethe Universität</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster (UKM)</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced acute leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

